Amarin Corp Plc (AMRN)

[sts66]

Is there a possibility the DMC has had ample time to gather/analyze what they need to in order to make a determination – especially if all secondary end points were met with overwhelming efficacy?

No way - they may not even be done with follow up visits with all patients yet. Secondary and subgroup analysis will slow down things quite a bit as well - can't automate everything, and in the end a real human has to look at results and see if they appear valid or if something odd pops out.

Case in point (not a drug trial, but similar enough to count) - I had thermal analysts that developed computer models of my systems to predict performance under different operating conditions. After a couple weeks of work one of them came to me with her results - the second I laid eyes on them I knew her model was way off somewhere, data literally violated some laws of thermodynamics - she had no clue how wrong the results were because she wasn't trained in the physics (more like biostats in AMRN's case), only knew how to create models and run the programs we used. This was not an isolated situation, it occurred with many analysts until they actually learned how the systems worked so they could realize when they were getting garbage out.